Still Not Much Momentum At Accuray
(WorldNews Health)

Small-cap oncology system manufacturer Accuray (ARAY) reported a decent fiscal fourth quarter, but it´s hard to see much momentum in the business or any real sign that this company is becoming a more disruptive force within the radiation oncology market. Although I continue to give management high marks for improving the underlying efficiency of the business and cleaning up the balance sheet, I just don´t see signs that Accuray is really gaining on Varian (VAR) (or even Elekta (OTCPK:EKTAY)) in any meaningful way, and I don´t see anything on the horizon that would drive a sudden shift in sentiment among customers. Valuation remains undemanding, and I still believe the acquisition of Accuray...